University of Regensburg has described water-soluble FLT3 (FLK2/STK1) inhibitors and their prodrugs reported to be useful for the treatment of acute myeloid leukemia (AML).
Universität Bonn has divulged P2X purinoceptor 4 (P2RX4; P2X4) antagonists reported to be useful as diagnostics and for the treatment of pain, inflammation, cancer, stroke, multiple sclerosis, atherosclerosis and obesity.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently bonded to a GTPase KRAS (G12D mutant) targeting moiety through a linker reported to be useful for the treatment of cancer.
Previous preclinical studies of the prodrug of cidofovir, NPP-669, have shown its oral bioavailability, excellent metabolic and pharmacokinetic parameters, as well as its broad-range activity against dsDNA viruses in vitro.
The bromodomain and extraterminal (BET) subfamily contain two similar tandem bromodomains (BD1 and BD2). Selective inhibition of BD2 has been deeply explored; however, the obtention of selective and potent BD1 inhibitors is essential and still lacking.
A researcher at Australia’s Children’s Cancer Institute has been awarded a 3-year US$400,000 grant by the Chadtough Defeat DIPG Foundation to develop and test a new drug candidate for diffuse intrinsic pontine glioma (DIPG).
Researchers from Children’s Hospital Boston and affiliated organizations have reported the discovery and preclinical characterization of a novel TLR7/8 agonist adjuvant for vaccination, PVP-037.
Nexthera Co. Ltd. has submitted an IND application to the FDA seeking to conduct a phase I/IIa trial with NT-101, a noninvasive eye drop treatment for wet age-related macular degeneration (AMD).
RSS
